Exclusive Summary

• Targeting a massive global market of over 1.28 billion hypertension patients, this WHO Essential Medicine and guideline-recommended first-line treatment guarantees exceptionally high inventory turnover.
• Backed by China's integrated API-to-FDF supply chain, the product offers significant cost competitiveness and supply stability for global distribution and public tenders against the originator (Cozaar).
• The 100 mg high-dose configuration (7/14 tablets per carton) perfectly aligns with the weekly/bi-weekly adherence habits of moderate-to-severe patients, making it ideal for rapid retail pharmacy sales.
• For emerging markets and regions lacking local manufacturing, this mature generic provides distributors with a highly compliant, easily registrable asset to quickly capture foundational chronic disease market share.